HRs for Effectiveness and Safety Outcomes in the IPTW
Cohorts
The annual rates and HRs for the primary analyses of the safety and
effectiveness composites in the IPTW treatment groups in an on-treatment
are shown in Supplementary Table S11 and Figure 4 (HRs only). With
warfarin as the reference group, rivaroxaban 15 mg and 20 mg were
associated with a similar effectiveness composite (HR 0.84; 95% CI
0.60–1.18 and HR 0.83; 95% CI 0.61–1.13, respectively); and similar
safety profile (HR 1.13; 95% CI 0.70–1.83 and HR 1.29; 95% CI
0.84–1.95, respectively). Apixaban 2.5 mg was associated with a similar
effectiveness (HR 1.00; 95% CI 0.79–1.26), but better safety (HR 0.65;
95% CI 0.43–0.99) profile, while apixaban 5.0 mg was associated with a
better effectiveness (HR 0.76; 95% CI 0.65–0.88), but a similar safety
risk (HR 0.94; 95% CI 0.66–1.35) profile. The observed improvement in
the effectiveness composite for apixaban 5.0 mg was driven by a
reduction in mortality (HR 0.61; 95% CI 0.43–0.88).